



# Talking with Your Waldenström Macroglobulinemia (WM) Patients

September 2022

This guide is provided  
courtesy of



and endorsed by  
our partners:



## Shayna Sarosiek, MD

Bing Center for Waldenström Macroglobulinemia

Division of Hematological Malignancies, Dana-Farber  
Cancer Institute

Assistant Professor, Harvard Medical School

## Jorge J. Castillo, MD

Clinical Director, Bing Center for Waldenström  
Macroglobulinemia

Division of Hematological Malignancies, Dana-Farber  
Cancer Institute

Associate Professor, Harvard Medical School



This publication is supported by Pharmacyclics,  
an AbbVie Company, and Janssen Biotech, Inc.

*Better understanding, better treatment—for a world without WM*



# CONTENTS

What is Waldenström Macroglobulinemia (WM)?.....	4
How common is WM and who is at risk?.....	4
Why did my patient get WM?.....	4
Are my patient’s children at risk for developing WM?.....	4
What is the life expectancy of a person with WM?.....	5
How can I confirm a diagnosis of WM and what tests should be performed prior to treatment?.....	5
Why should CXCR4 status be evaluated?.....	6
Does everyone need treatment at the time of diagnosis?.....	6
What are the criteria for treatment of WM?.....	6
What work-up should be done in the setting of worsening anemia in a patient with WM?.....	6
What symptoms should I and my patients monitor for?.....	7
How common is neuropathy in WM and how should it be evaluated?.....	7
What are the most common symptoms of hyperviscosity?.....	7
What should be done if I am concerned that my patient has symptomatic hyperviscosity?.....	8
What are the treatment options?.....	8
How is Bing-Neel syndrome diagnosed and treated?.....	9
Patient Resources.....	10
References.....	13

# About the condition

## Waldenström Macroglobulinemia (WM)

### What is Waldenström Macroglobulinemia?

Waldenström macroglobulinemia (WM) is an indolent lymphoma characterized by the presence of lymphoplasmacytic cells which secrete an IgM monoclonal paraprotein.<sup>1</sup> The clonal lymphoplasmacytic cells in WM can be present in the bone marrow at any concentration, but may also be found in the lymph nodes, spleen, liver or other extramedullary locations. Patients with a serum monoclonal IgM in the absence of a detectable bone marrow clone and with no

associated clinical signs or symptoms related to the IgM paraprotein are characterized as having a monoclonal gammopathy of undetermined significance (MGUS). An MYD88 L265P mutation is detectable in up to 50% of patients with IgM MGUS, but is found in >90% of patients with WM. The presence of an MYD88 mutation can help distinguish WM from other hematologic disorders, such as multiple myeloma, in which MYD88 mutations are not found.<sup>2-5</sup>

### How common is WM and who is at risk?

WM is a rare lymphoma that affects 3-4 persons per million.<sup>6</sup> It is more common in men than women and is also more common in White patients, particularly of European descent, compared with other races/ethnicities.<sup>7</sup> This is

a disease that occurs in older patients with an average age of diagnosis of approximately 70 years.<sup>8</sup> Having an IgM MGUS poses a cumulative risk of developing WM of 1% per year.<sup>9</sup>

### Why did my patient get WM?

The exact etiology of WM is unclear. It develops spontaneously with no known predisposing factors or causes in most cases, although there are data relating the development of WM to underlying chronic inflammation

or autoimmune disorders.<sup>10,11</sup> Additionally, familial clustering has been reported in WM with approximately 19% of all patients with WM having a first-degree relative with WM or another B-cell disorder.<sup>11</sup>

### Are my patient's children at risk for developing WM?

Waldenström macroglobulinemia is typically not directly inherited. Having a family member with WM does increase the risk of developing WM, another non-Hodgkin lymphoma, or MGUS but the relative risk remains low.<sup>11,12</sup> Despite this slightly increased

risk of hematologic disorders in family members of WM patients, in the absence of concerning signs or symptoms it is generally not recommended that other family members be screened for WM.<sup>10</sup>

## What is the life expectancy of a person with WM?

---

Most patients with WM will live for many years and potentially even decades. In many cases, especially young patients with WM, life expectancy is matched with gender-specific, age-specific matched cohorts and patients will likely die from something unrelated to WM.<sup>13</sup> The International Prognostic Scoring System for WM (IPSSWM) can be used to further define a patient's risk group by using age, hemoglobin, platelets,  $\beta$ -2-microglobulin, and IgM.<sup>14</sup> In recent years this scoring system was revised (rIPSSWM) and now includes age,

$\beta$ -2-microglobulin, lactate dehydrogenase (LDH), and albumin.<sup>15</sup> In both of these scoring systems age is weighed most heavily as a risk factor. When using the IPSSWM or rIPSSWM it must be taken into account that these systems were developed at a time before the current, most effective standard therapies were widely available, so it is expected that prognosis has improved since the development of these scoring systems. In addition, these prognostic tools aim at estimating survival from first line therapy initiation and not at diagnosis.

## How can I confirm a diagnosis of WM and what tests should be performed prior to treatment?

---

The criteria to confirm a diagnosis of WM include the presence of a monoclonal IgM paraprotein (which can be detected on serum immunofixation electrophoresis) and a lymphoplasmacytic infiltrate in the bone marrow.<sup>16</sup> The clonal infiltration in the bone marrow is typically positive for expression of surface IgM, CD19, CD20, CD25 and CD27.<sup>17</sup> Although CD5, CD10 and CD23 are not typically expressed they may be present in a minority of cases. In addition to the diagnostic utility of a bone marrow biopsy, a bone marrow aspirate should also be obtained in patients with suspected WM to evaluate the MYD88 mutational status, in addition to evaluating the mutational status of CXCR4. An MYD88 mutation will be detected in more than 90% of patients with WM.<sup>2,3</sup> CXCR4 mutations are found in approximately 30-40% of patients with WM. The MYD88 and CXCR4 mutational status may influence clinical manifestations of the disease as well as treatment options.<sup>18-22</sup> Additional baseline labs, such as complete blood counts, comprehensive metabolic panel, serum immunofixation electrophoresis, serum protein electrophoresis, immunoglobulins, serum viscosity (if concern for symptomatic

hyperviscosity),  $\beta$ -2-microglobulin, cryoglobulins, and cold agglutinins may be helpful for full disease assessment. Prior to initiating therapy, it is also important to obtain baseline CT scans to evaluate for sites of extramedullary disease and splenomegaly. This imaging is not required at the time of diagnosis for asymptomatic patients.

Of note, in an era of rapidly evolving research it can be helpful to have the input of a specialist with an in-depth understanding of the nuances and complexities of the highly variable clinical presentation of WM, as well as the genetic and molecular characteristics of the disease. There are multiple physicians throughout the US and in other countries who specialize in WM and would be willing to evaluate your patient and continue to collaborate with you for ongoing patient care. Contact information for many WM specialists can be found through the International Waldenström's Macroglobulinemia Foundation (IWMMF) physician directory.

## Why should CXCR4 status be evaluated?

---

Patients with CXCR4 mutations are more likely to present with higher serum IgM levels, increased bone marrow burden of disease, increased risk of hyperviscosity, and increased risk of acquired von Willebrand syndrome.<sup>23</sup> Knowing the CXCR4 mutational status can help predict responses to therapy, as it has been noted that the time to response, depth

of hematologic response, and the length of progression free survival is shorter with BTK inhibitors such as ibrutinib.<sup>24</sup> The rate of major response was also shown to be lower in patients with CXCR4 mutations treated with either ibrutinib or zanubrutinib when compared with patients that have wild-type CXCR4.<sup>25</sup>

## Does everyone need treatment at the time of diagnosis?

---

Not everyone who is diagnosed with WM requires treatment at the time of diagnosis. Within two years of diagnosis approximately 30% of patients will require treatment, but there are about 20-30% of patients that will not require treatment even 10 years after diagnosis of WM.<sup>26,27</sup> It can be helpful to use albumin,

serum IgM level, percent of bone marrow infiltration, and  $\beta$ -2-microglobulin to calculate the median time to disease progression to assist asymptomatic patients in understanding when they may require treatment. (awmrisk.com)

## What are the criteria for treatment of WM?

---

There are specific guidelines for initiation of therapy, including the development of symptomatic anemia with a hemoglobin  $\leq 10$  g/dL (secondary to the WM), platelets  $< 100,000$  mm<sup>3</sup>, symptomatic hyperviscosity, moderate to severe neuropathy, symptomatic extramedullary disease, or other symptomatic complications of the disease such as cold agglutininemia, cryoglobulinemia, or amyloidosis.<sup>28,29</sup>

It is also important to recognize that although patients have an increased risk of

hyperviscosity when IgM reaches  $\geq 4,000$  mg/dL, there is no need to treat asymptomatic patients based only on the serum IgM level or serum viscosity. The risk of hyperviscosity increases with the IgM level and for those patients with an IgM  $> 6000$  mg/dL at the time of diagnosis the median time to symptomatic hyperviscosity is approximately 3 months compared with those patients with an IgM of 5000-6000 mg/dL that have a median time of 3 years until development of symptomatic hyperviscosity.<sup>30</sup>

## What work-up should be done in the setting of worsening anemia in a patient with WM?

---

If a patient with WM has developed significant anemia, prior to offering WM-directed therapy it is important to ensure there is no other cause for the anemia. Work-up should be performed to evaluate for other etiologies of anemia such as B12, folate or iron deficiency. If iron deficiency is discovered a thorough work-up

for bleeding, especially gastrointestinal, should be performed. If no alternative source of iron deficiency is discovered the iron deficiency may be a result of the WM. Approximately 25% of patients with WM develop iron deficiency related to production of hepcidin from malignant cells.<sup>31,32</sup> In such cases, intravenous

iron may be used to improve the patient's hemoglobin. Hemolysis is a rare cause for anemia in patients with WM and could be

associated with warm auto-antibodies or cold agglutinins.

## What symptoms should I and my patients monitor for?

---

Although symptomatic anemia is the most common presentation of WM, additional signs and symptoms of the disease can vary widely and may include:<sup>33</sup>

Constitutional symptoms (fatigue, weight loss, night sweats, and unexplained fevers)

Splenomegaly (early satiety, left upper quadrant pain or fullness)

Hyperviscosity (nosebleeds, headaches, blurred vision)

Peripheral neuropathy (bilateral, symmetrical, length-dependent, sensory deficits)

Cold agglutinin disease (anemia and dark colored urine when exposed to cold temperatures)

Cryoglobulinemia (livedo reticularis, discoloration of hands, feet, nose tip, or ears when exposed to cold temperatures)

Amyloidosis (nephrotic syndrome, cardiomyopathy, rapidly progressing neuropathy)

Bing-Neel syndrome (headaches, seizure, facial paralysis, limb weakness)

## How common is neuropathy in WM and how should it be evaluated?

---

Neuropathy is present in approximately 25% of patients with WM at the time of diagnosis.<sup>34</sup> Typically, IgM-related neuropathy is bilateral and symmetrical, slowly progressive (years), length-dependent and predominantly sensory. In many cases the neuropathy is related to the presence of an anti-myelin associated glycoprotein (anti-MAG) antibody, but anti-ganglioside and anti-sulfatide antibodies have also been reported. Neuropathy mediated by an anti-MAG antibody typically presents as a sensorimotor polyneuropathy with

demyelinating features on electromyography and nerve conduction studies (EMG/NCS). Less commonly, neuropathy can be related to amyloidosis or cryoglobulinemia. A thorough evaluation by a neurologist, including an EMG/NCS, history and physical exam, is important in patients with rapidly progressive neuropathy or neuropathy that is significantly affecting a patient's quality of life to confirm the etiology of the neuropathy prior to initiating therapy for WM.

## What are the most common symptoms of hyperviscosity?

---

Hyperviscosity symptoms can include bleeding (commonly nosebleeds or spontaneous oral bleeding), vision changes, or central nervous system symptoms such as headache, dizziness, or seizure. Blurred vision can occur, usually related to retinal vessel engorgement or retinal

bleeding. Patients at risk for hyperviscosity should have annual or semi-annual eye exams to ensure there are no signs of hyperviscosity, such as retinal vessel hemorrhages, retinal or optic nerve head edema or retinal vein dilation.<sup>35</sup>

## What should be done if I am concerned that my patient has symptomatic hyperviscosity?

If there is concern for hyperviscosity then serum IgM level and serum viscosity can be measured. Typically, a serum viscosity  $\leq 4$  centipoise does not lead to clinical symptoms of hyperviscosity. Serum viscosity is often not readily available and in most cases a serum IgM level is sufficient to determine the risk of hyperviscosity with an IgM  $\geq 6,000$  mg/dL having an incidence of hyperviscosity of approximately 67%.<sup>30</sup> An exam and thorough

history should be performed in patients with elevated serum IgM to evaluate for clinical signs or symptoms of hyperviscosity.

In the case of symptomatic hyperviscosity patients should be treated with plasmapheresis to reduce the serum IgM and alleviate clinical signs/symptoms of hyperviscosity. At least 1-2 sessions of plasma exchange can be performed as a bridging therapy while definitive treatment is initiated.

## What are the treatment options?

Treatment options for WM vary and should be chosen based on each patient's disease characteristics and patient-specific factors, such as age, performance status, co-morbidities, and treatment preferences.

In recent years, as cancer directed therapies have moved more towards targeted treatments, BTK inhibitors have become a mainstay in first-line therapy of WM. The FDA has approved both ibrutinib (+/- rituximab) and zanubrutinib as options for first line therapy in WM due to the high response rate and acceptable safety profile.<sup>25,36,37</sup> There are also data for using acalabrutinib in WM, although it is not FDA approved in WM.<sup>38</sup> BTK inhibitors are a preferred treatment option in many patients, although alternative options can be considered especially in patients with MYD88 wild-type or CXCR4 mutated disease. The adverse effects associated with BTK inhibitors include risks of bleeding, infection, gastrointestinal symptoms, cytopenias, arthralgias or myalgias, and atrial fibrillation. Recent data confirm that newer BTK inhibitors, such as zanubrutinib, have the same disease efficacy as ibrutinib but with less off-target effects.<sup>25</sup>

Bendamustine-rituximab is also a common first-line treatment option that has a finite duration of treatment (4-6 cycles) and has efficacy, independent of the CXCR4

mutational status.<sup>39-41</sup> Rituximab-bortezomib-dexamethasone, in addition to other proteasome inhibitor-based regimens, are also potential treatment options, although consideration must be made for the potential side effect of neuropathy especially in patients with baseline neuropathy related to their WM.<sup>42,43</sup> In patients with an IgM  $>4,000$  mg/dL rituximab should not typically be given due to the risk of IgM flare.<sup>44,45</sup> In those cases, bendamustine or the proteasome inhibitor can be given for 1-2 cycles with rituximab added at a later date. Of note, approximately 10% of patients with WM will develop intolerance to rituximab and in this case ofatumumab can be substituted for rituximab per the NCCN guidelines.<sup>46</sup>

In the relapsed setting any of the above mentioned therapies can be considered if not previously utilized.<sup>47-49</sup> In addition, a two year course of venetoclax can also be used for treatment of relapsed or refractory WM.<sup>50</sup>

Importantly, when feasible clinical trials should be considered for patients with newly diagnosed or relapsed disease, as patient enrollment in clinical trials is incredibly important for the development of new therapies in rare diseases such as WM.



## How is Bing-Neel syndrome diagnosed and treated?

---

Bing-Neel syndrome (BNS) is a rare manifestation of WM that occurs in approximately 1% of patients and is characterized by the infiltration of malignant cells into the central nervous system.<sup>51,52</sup>

Bing-Neel syndrome can occur at the time of initial WM diagnosis or later in the disease course. The clinical presentation of Bing-Neel syndrome can vary widely, but common symptoms include cognitive changes, behavioral changes, seizures, headaches, gait/balance abnormalities, cranial nerve deficits, or paresis. Evaluation for potential Bing-Neel syndrome should include cerebral spinal fluid (CSF) evaluation and MRI (with gadolinium) of the brain and the spine, including cervical, thoracic, and lumbar regions. Typical findings

of BNS on MRI may include either tumoral involvement or leptomeningeal enhancement. Lumbar puncture should be performed for complete evaluation and CSF should be sent for flow cytometry, cytology, IGH rearrangement, and MYD88 testing. If Bing-Neel syndrome is diagnosed the preferred first-line therapy is a BTK inhibitor. The most robust data in this setting support the use of ibrutinib, although early data suggest that zanubrutinib may also be a potential treatment.<sup>53</sup> In the case of relapsed or refractory BNS, other chemotherapy based regimens such as bendamustine/rituximab, fludarabine/rituximab, or intrathecal therapy can be considered.

# Patient Resources

Partners working for a world without WM.



## The International Waldenstrom's Macroglobulinemia Foundation (IWMF)

[www.iwmf.com](http://www.iwmf.com)

**Phone:** 941-927-4963

**International** 001-941-927-4963

The IWMF, the only international organization dedicated solely to Waldenstrom's macroglobulinemia (WM), is a patient-founded and patient-directed nonprofit with a simple but compelling vision and mission.

**OUR VISION:** A world without WM (Waldenstrom's macroglobulinemia)

**OUR MISSION:** Support and educate everyone affected by Waldenstrom's macroglobulinemia (WM) while advancing the search for a cure.

The IWMF is committed to creating a world without WM by finding a cure. Since 1999, the IWMF has invested over \$21 million in WM research projects throughout the world. Thanks to this research, WM patients are living longer, and have better treatment options that can lead to longer-lasting remissions, with fewer side effects.

### Visit the IWMF website to:

- Download a free Newly Diagnosed Info Pak.
- Download free publications about WM written in a clear, easy-to-understand style and available in multiple languages.
- Join a local IWMF Support Group or global affiliate.
- Join IWMF Connect, an online community offering a wide variety of moderated WM-related email discussions, or IWMF Facebook.
- Attend the annual IWMF Educational Forum or our online webinars.
- Subscribe to the IWMF Torch, our free quarterly newsletter.

Although WM is a rare disease, with the IWMF you are never alone.



## CancerCare

[www.cancercares.org](http://www.cancercares.org)

**Phone:** 800 813 HOPE (4673)

Founded in 1944, CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. Our comprehensive services include case management, counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. All CancerCare services are provided by master's-prepared oncology social workers and world-leading cancer experts.



## Cancer Support Community (CSC)

[www.CancerSupportCommunity.org](http://www.CancerSupportCommunity.org)

**Phone:** 888-793-9355

As the largest professionally led nonprofit network of cancer support worldwide, the Cancer Support Community (CSC), including its Gilda's Club affiliates, is dedicated to ensuring that all people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community. CSC achieves its mission through three areas: direct service delivery, research, and advocacy. The organization's Institute for Excellence in Psychosocial Care includes an international network of affiliates that offer the highest quality social and emotional support for people impacted by cancer, as well as a community of support available online and over the phone. The Research and Training Institute conducts cutting-edge psychosocial, behavioral, and survivorship research. CSC furthers its focus on patient advocacy through its Cancer Policy Institute, informing public policy in Washington, D.C. and across the nation.



## Leukemia & Lymphoma Society (LLS)

[www.lls.org](http://www.lls.org)

**Phone:** 800-955-4572

The Leukemia & Lymphoma Society® is the global leader in the fight against blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has regions throughout the United States and Canada. To learn more, visit [www.LLS.org](http://www.LLS.org). Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

For additional information visit [lls.org/lls-newsnetwork](http://lls.org/lls-newsnetwork). Follow us on Facebook, Twitter, and Instagram.



## Lymphoma Coalition (LC)

[www.lymphomacoalition.org](http://www.lymphomacoalition.org)

Lymphoma Coalition is a worldwide network of patient organisations that support those affected by lymphoma. LC acts as a central hub for reliable and current information, as well as advocating for equitable care globally. Its mission is to enable global impact by fostering a lymphoma ecosystem that ensures local change and evidence-based action. Today, there are more than 80 member organisations from over 50 countries.



## Lymphoma Research Foundation (LRF)

[www.lymphoma.org](http://www.lymphoma.org)

**LRF Helpline:** 800-500-9976

The Lymphoma Research Foundation (LRF) is the nation's largest non-profit organization devoted *exclusively* to funding lymphoma research and supporting the lymphoma community through evidence-based education, support services, and resources.



# References

## Waldenström Macroglobulinemia (WM)

1. Owen RG, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. *Seminars in oncology*. 2003;30(2):110-115.
2. Treon SP, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. *N Engl J Med*. 2012;367(9):826-833.
3. Xu L, et al. MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. *Blood*. 2013;121(11):2051-2058.
4. Correa JG, et al. Prevalence and prognosis implication of MYD88 L265P mutation in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenstrom macroglobulinaemia. *Br J Haematol*. 2017;179(5):849-851.
5. Varettoni M, et al. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. *Blood*. 2013;122(13):2284-2285.
6. Sekhar J, et al. Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. *Leuk Lymphoma*. 2012;53(8):1625-1626.
7. Benjamin M, Reddy S, Brawley OW. Myeloma and race: a review of the literature. *Cancer Metastasis Rev*. 2003;22(1):87-93.
8. Castillo JJ, et al. Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. *Br J Haematol*. 2015;169(1):81-89.
9. Kyle RA, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. *Blood*. 2003;102(10):3759-3764.
10. Manasanch EE, Kristinsson SY, Landgren O. Etiology of Waldenstrom macroglobulinemia: genetic factors and immune-related conditions. *Clin Lymphoma Myeloma Leuk*. 2013;13(2):194-197.
11. Treon SP, et al. Characterization of familial Waldenstrom's macroglobulinemia. *Ann Oncol*. 2006;17(3):488-494.
12. Kristinsson SY, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. *Blood*. 2008;112(8):3052-3056.
13. Varettoni M, et al. Younger patients with Waldenstrom Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. *Am J Hematol*. 2020;95(12):1473-1478.
14. Morel P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. *Blood*. 2009;113(18):4163-4170.
15. Kastritis E, et al. A revised international prognostic score system for Waldenstrom's macroglobulinemia. *Leukemia*. 2019;33(11):2654-2661.
16. Owen RG, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus

panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. *Semin Oncol*. 2003;30(2):110-115.

17. Paiva B, et al. Multiparameter flow cytometry for the identification of the Waldenstrom's clone in IgM-MGUS and Waldenstrom's Macroglobulinemia: new criteria for differential diagnosis and risk stratification. *Leukemia*. 2014;28(1):166-173.
18. Hunter ZR, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. *Blood*. 2014;123(11):1637-1646.
19. Treon SP, et al. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. *Br J Haematol*. 2018;180(3):374-380.
20. Castillo JJ, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstrom macroglobulinaemia treated with ibrutinib. *Br J Haematol*. 2019;187(3):356-363.
21. Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP. CXCR4 mutations affect presentation and outcomes in patients with Waldenstrom macroglobulinemia: A systematic review. *Expert Rev Hematol*. 2019;12(10):873-881.
22. Xu L, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia. *Br J Haematol*. 2016;172(5):735-744.
23. Treon SP, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. *Blood*. 2014;123(18):2791-2796.
24. Treon SP, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia. *J Clin Oncol*. 2021;39(6):565-575.
25. Tam CS, et al. A Randomized Phase 3 Trial of Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: The Aspen Study. *Blood*. 2020.
26. Bustoros M, et al. Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia. *J Clin Oncol*. 2019;37(16):1403-1411.
27. Kyle RA, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. *Blood*. 2012;119(19):4462-4466.
28. Kyle RA, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. *Semin Oncol*. 2003;30(2):116-120.
29. Castillo JJ, et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia. *Br J Haematol*. 2016;175(1):77-86.
30. Gustine JN, et al. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenstrom macroglobulinaemia. *Br J Haematol*. 2017;177(5):717-725.
31. Ciccarelli BT, et al. Hpcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2011;11(1):160-163.
32. Treon SP, et al. Patients with Waldenstrom macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration. *Clin Lymphoma Myeloma Leuk*. 2013;13(2):241-243.
33. Dimopoulos MA, Kastiris E. How I treat Waldenstrom macroglobulinemia. *Blood*. 2019;134(23):2022-2035.
34. Paba-Prada C, Banwait R, Treon S, Ghobrial I. Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis. *Blood*. 2011;118(21):3692.
35. Menke MN, et al. Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. *Arch Ophthalmol*. 2006;124(11):1601-1606.

36. Dimopoulos MA, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. *Lancet Oncol.* 2017;18(2):241-250.
37. Treon SP, et al. Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia. *J Clin Oncol.* 2018;36(27):2755-2761.
38. Owen RG, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. *Lancet Haematol.* 2020;7(2):e112-e121.
39. Flinn IW, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. *J Clin Oncol.* 2019;37(12):984-991.
40. Laribi K, et al. Bendamustine plus rituximab in newly-diagnosed Waldenstrom macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). *Br J Haematol.* 2019;186(1):146-149.
41. Rummel MJ, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. *Lancet.* 2013;381(9873):1203-1210.
42. Buske C, et al. Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First – Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial. *Blood.* 2020;136(Suppl 1):26.
43. Dimopoulos MA, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). *Blood.* 2013;122(19):3276-3282.
44. Ghobrial IM, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. *Cancer.* 2004;101(11):2593-2598.
45. Treon SP, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. *Ann Oncol.* 2004;15(10):1481-1483.
46. Castillo JJ, et al. Rituximab intolerance in patients with Waldenstrom macroglobulinaemia. *Br J Haematol.* 2016;174(4):645-648.
47. Tedeschi A, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. *Leuk Lymphoma.* 2015;56(9):2637-2642.
48. Ghobrial IM, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. *J Clin Oncol.* 2010;28(8):1422-1428.
49. Treon SP, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma Leuk.* 2011;11(1):133-135.
50. Castillo JJ, et al. Venetoclax in Previously Treated Waldenstrom Macroglobulinemia. *J Clin Oncol.* 2022;40(1):63-71.
51. Minnema MC, et al. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. *Haematologica.* 2017;102(1):43-51.
52. Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. *Br J Haematol.* 2019;187(3):277-285.
53. Wong J, et al. Efficacy of Zanubrutinib in the Treatment of Bing-Neel Syndrome. *Hemasphere.* 2018;2(6):e155.



6144 Clark Center Ave, Sarasota, FL 34238  
TEL: 941-927-4963 • email: [INFO@IWMF.COM](mailto:INFO@IWMF.COM)  
**IWMF.COM**

  
**IMAGINE**  
— A CURE —

